Tag Archives: DM4

02Mar/23

Platinum-Resistant Ovarian Cancer to Create New Drugs! FDA Approved ADC Elahere

March 2, 2023Antibody-drug Conjugates Researchantibody-drug conjugate, DM4, Maytansinoidbioadc

In November 2022, ImmunoGen announced that the Food and Drug Administration (FDA) has accelerated the approval for Elahere (mirvetuximab soravtansine-gynx): a monotherapy for adult patients with epithelial ovarian, fallopian, and primary peritonealRead More…

31Jul/22

About ADCs Payloads: Microtubule-destroying Drug

July 31, 2022ReviewADCs Payloads, Auristatin F, DM4, Microtubule-destroying drugsbioadc

Antibody-drug conjugate (ADC) is formed by linking monoclonal antibodies targeting specific antigens with small molecular cytotoxic drugs through linkers, which have both the strong killing effect of traditional small molecule chemotherapy andRead More…

24Nov/21

Ushering in a “Raging” Era—Fiercely Competitive Phase III ADCs (part I)

November 24, 2021ReviewADC Therapy, CEACAM5, DM4, Phase III ADCsbioadc

An antibody-drug conjugate (ADC) is composed of an antibody, a chemical linker, and a small molecular payload, and takes advantage of the specific targeting binding ability of antibody to transport cytotoxic payloadRead More…